Aripiprazol
Eine medikamentöse Behandlungsalternative beim Tourette-Syndrom im Kindes- und Jugendalter
Abstract
Fragestellung: Fallberichte von sieben Patienten mit Ticstörungen mit einer Krankheitsdauer von mindestens zwei Jahren sollen Hinweise zur Wirksamkeit des partiellen Dopamin-Agonisten, Aripiprazol, geben, welches sich in der Behandlung von Ticstörungen als wirksam und gut verträglich erwiesen hat. Methodik: Fünf Patienten mit einem Tourette-Syndrom (TS) und zwei mit chronisch motorischer Ticstörung (Alter 8;7–18;1 Jahre), bei denen zuvor eingesetzte Neuroleptika ungenügend wirksam waren oder wegen nicht tolerierbarer Nebenwirkungen abgesetzt werden mussten, wurden mindestens acht Wochen lang mit Aripiprazol behandelt. Vor und nach der Behandlung beantworteten die Eltern der Patienten das Ausmaß der vokalen und motorischen Ticsymptomstärke auf der Yale-Tourette-Syndrom-Symptomliste. Ergebnisse: Innerhalb des Beobachtungszeitraums kam es zu einem deutlichen Rückgang der motorischen Ticsymptomatik um 66 % sowie zu einem Rückgang der vokalen Ticsymptomstärke um 26 %, bei einer mittleren Tagesdosis von 14.3 mg (min. 5 mg, max. 30 mg). Symptome einer komorbiden Aufmerksamkeitsdefizit-Störung sowie einer Zwangserkrankung wurden durch die Behandlung nicht wesentlich beeinflusst. Während der Behandlung traten leichte Nebenwirkungen wie Bauchschmerzen, Müdigkeit und Weinerlichkeit auf. Behandlungsabbrüche wurden nicht beobachtet. Schlussfolgerungen: Aripiprazol stellt womöglich eine wirkungsvolle und gut verträgliche, nebenwirkungsarme Alternative zur bisher üblichen neuroleptischen Behandlung von Ticstörungen dar. Die Wirksamkeit, insbesondere im Hinblick auf Komorbiditäten, sollte in klinisch kontrollierten Studien verifiziert werden.
Objective: We report a case-series of seven patients with a medical history of at least two years of tic disorder treated with the partial dopamine agonist aripiprazole to illustrate its efficacy as a treatment alternative for motor and vocal tics in children and adolescents. Method: A case series of five patients with Tourette Syndrome (TS) and two with chronic motor tic disorder (age range 8; 7–18; 1 year), the majority of whom had been refractory to treatment with other neuroleptics or had ceased treatment due to intolerable side effects, were treated for eight weeks with aripiprazole. Before and after treatment, parents rated the severity of motor and vocal tic symptoms on the Yale Tourette Syndrome Checklist. Results: Within eight weeks mean motor tic symptoms decreased by 66% and mean vocal tic symptoms decreased by 26%. Mean effective dosage was 14.3 mg/day (min. 5 mg, max. 30 mg). Symptoms of comorbid ADHD or Obsessive Compulsive Disorder were not significantly influenced. During medication only mild side effects were observed, e.g., abdominal pain, fatigue and increased emotional sensitivity. No patient dropped out of treatment due to side effects. Conclusions: Aripiprazole may be an effective pharmacologic treatment alternative for individuals with chronic motor tic disorder and TS. It induces quick, significant and sustained effects with few generally mild and transient side effects, if anything. Its effectiveness, especially relative to comorbidities, should be verified in double-blind, placebo-controlled studies.
Literatur
2007). Comorbidity of tic disorders; ADHD: Conceptual and methodological considerations. European Child and Adolescent Psychiatry, 16(Suppl. 1), 5–14.
(2003). Compulsive phenomena in children with tic disorder and attention deficit-hyperactive disorder. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 31, 203–211.
(2004). Quetiapine for chronic motor tic disorder. American Journal of Psychiatry, 161, 1307.
(2003). Aripiprazole: A new atypical antipsychotic drug. Annals of Pharmacotherapy, 37, 687–694.
(2001). Risperidone versus pimozide in Tourette’s disorder: A comparative double-blind parallel-group study. Journal of Clinical Psychiatry, 62, 50–56.
(1988). Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. American Journal of Psychiatry, 145, 621–624.
(2006). Aripiprazole in patients with Tourette syndrome. World Journal of Biological Psychiatry, 7, 123–125.
(2008). Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Journal of Child and Adolescent Psychopharmacology, 18, 509–515.
(2001). An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder. Journal of Clinical Psychiatry, 62, 290–294.
(2004). Clinical phenomenology of episodic rage in children with Tourette syndrome. Journal of Psychosomatic Research, 55, 59–65.
(1994). Developmental psychopathology and neurobiology of Tourette’s syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 2–15.
(2005). The use of aripiprazole in obsessive-compulsive disorder: Preliminary observations in 8 patients. Journal of Clinical Psychiatry, 66, 49–51.
(2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry, 161, 414–425.
(2006). A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Human Psychopharmacology: Clinical and Experimental, 21, 447–453.
(2005). Aripiprazole in a patient vulnerable to side effects. American Journal of Psychiatry, 162, 625.
(2004). Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy and tolerability. Clinical Therapeutics, 26, 649–666.
(2008). Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F). Diagnostische Kriterien für Forschung und Praxis. Bern: Huber.
(2002). Risperidone in the treatment of tourette syndrome: A double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 22, 31–39.
(2010). Ticstörungen. Manuskript in Vorbereitung.
(1988). Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. European Archives of Psychiatry and Clinical Neuroscience, 237, 223–229.
(2007). Pharmacotherapy of aggression in a 9-year-old with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 653–658.
(2006). Acute dystonia with low-dosage Aripiprazole in Tourette’s disorder. Annals of Pharmacotherapy, 40, 775–777.
(2000). An international perspective on Tourette syndrome: Selected findings from 3500 individuals in 22 countries. Developmental Medicine and Child Neurology, 42, 436–447.
(2009). Coprophenomena in Tourette-Syndrome. Developmental Medicine and Child Neurology, 51, 218–227.
(2002). Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 330–336.
(2003). Developmental processes and brain imaging studies in Tourette syndrome. Journal of Psychosomatic Research, 55, 13–22.
(2004). Tic reduction with risperidone versus pimozide in an randomized double blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 206–214.
(2004). Co-existing disorders in ADHD-implications for diagnosis and intervention. European Child and Adolescent Psychiatry, 13(Suppl. 1), I80–92.
(2006). Aripiprazole: Pharmacodynamics of dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry, 39(Suppl. 1), s21–25.
(1997). Rates for tic disorders and obsessive compulsive symptomatology in families of children and adolescents with Gilles de la Tourette syndrome. Psychiatry Research, 31, 519–30.
(2004). Case study: Severe self-injurious behavior in comorbid Tourette’s disorder and OCD. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1296–1303.
(2004). Aripiprazol e syndrome de Tourette [Aripiprazol and Tourette’s syndrome]. Revista Brasileira de Psiquiatria, 26(3), 213.
(1992). Relationship of birth weight to the phenotypic expression of Gilles de la Tourette’s syndrome in monozygotic twins. Neurology, 42, 652–8.
(2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic induced cortical dopamine release. Journal of Neurochemistry, 76, 1521–1531.
(2001). Tourette syndrome. New England Journal of Medicine, 85, 369–390.
(2001). Weight change and atypical antipsychotic treatment in patients with schizophrenia. Journal of Clinical Psychiatry, 62(Suppl. 2), 41–44.
(2005). Treatment of tics in Tourette syndrome with aripiprazole. Journal of Clinical Psychopharmacology, 25, 94–96.
(2001). Quetiapine and obsessive-compulsive symptoms (OCS): Case report and review of atypical antipsychotic-induced OCS. Journal of Neuropsychiatry and Clinical Neurosciences, 26(1), 55–59.
(2005). Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorder in Korea. Journal of Child and Adolescent Psychopharmacology, 15, 318–423.
(2001). Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry, 62, 92–100.
(2007). Sleep behavior in children with tic disorders – a polysomnographic study. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 35, 119–126.
(1997). Asymmetry of basal ganglia perfusion in Tourette’s syndrome shown by technetium-99-m-HMPAO SPECT. Journal of Nuclear Medicine, 38, 188–191.
(2002). Tourette’s syndrome. Lancet, 360, 1577–1586.
(1997). Pathogenesis of Tourette’s syndrome. Journal of Child Psychology and Psychiatry, 38, 119–142.
(2006). Annotation: Tourette syndrome: A relentless drumbeat-driven by misguided brain oscillations. Journal of Child Psychology and Psychiatry, 47, 537–550.
(2006). Quetiapine in the treatment of tic disorder. Annals of Pharmacotherapy, 40, 1472.
(2002). Depression and dysphoria in adult adolescents patients with Tourette’s disorder treated with risperidone. Journal of Clinical Psychiatry, 63, 1040–1044.
(2004). Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. Journal of Clinical Psychiatry, 65, 20–29.
(1999). Nachbarschaft von Tic und Zwang. Nervenarzt, 70, 1–10.
(1999). Deficient motor control in children with tic disorder: evidence from transcranial magnetic stimulation. Neuroscience Letters, 272(1), 37–40.
(2007). Die Benzamide Tiaprid, Sulpirid und Amisulprid in der Therapie des Tourette-Syndroms. Nervenarzt, 78, 264–271.
(2000). Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurologica Scandinavica, 101, 1–7.
(2003). Quetiapine treatment of children and adolescents with Tourette’s disorder. Journal of Child and Adolescent Psychopharmacology, 13, 295–299.
(2005). Case series on the use of aripiprazole for Tourette syndrome. International Journal of Neuropsychopharmacology, 8, 489–490.
(2000). Olanzapine in severe Gilles de la Tourette syndrome: A 52-week double-blind cross-over study vs. low-dose pimozide. Journal of Neurology, 247, 443–446.
(2001). Quetiapine treatment of children with Tourette’s syndrome: Report of two cases. Journal of Child and Adolescent Psychopharmacology, 11, 187–191.
(2000). Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in tic, obsessive-compulsive, and attention deficit/hyperactivity disorders. Archives of General Psychiatry, 57, 364–372.
(2006). Tic disorders: From pathophysiology to treatment. Journal of Neurology, 253, 1–15.
(1987). Tardive dyskinesia following haloperidol treatment in Tourette’s syndrome. Archives of General Psychiatry, 44, 98–99.
(2006). Attention Deficit hyperactivity disorder and Tourette syndrome: The relationship and treatment implications. A commentary. European Child and Adolescent Psychiatry, 15, 1–11.
(2008). The International Prevalence, Epidemiology and Clinical Phenomenology of Gilles de la Tourette Syndrome: Part 1 – The epidemiological and prevalence studies. Journal of Psychosomatic Research, 65, 473–486.
(2004). Therapie der Tic-Störungen. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 4, 245–263.
(2007). Developmental psychopathology of children and adolescents with Tourette syndrome-impact of ADHD. European Child and Adolescent Psychiatry, 16(Suppl. 1), 24–35.
(2007a). Executive functions in children with chronic tic disorders with/without ADHD. New insights. European Child and Adolescent Psychiatry, 16(Suppl. 1), 36–44.
(2007b). Psychopathological profile in children with chronic tic disorder and co-existing ADHD: Additive effects. Journal of Abnormal Child Psychology, 35(1), 79–85.
(2000). Ziprasidone treatment of children and adolescents with Tourette’s syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 292–299.
(1997). Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. American Journal of Psychiatry, 154, 1057–1062.
(2006). Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx, 3, 192–206.
(2003). A placebo-controlled trial of risperidone in Tourette-Syndrome. Neurology, 60, 1130–1135.
(2008). Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. Journal of Child and Adolescent Psychopharmacology, 18, 197–205.
(1984). Controlled study of pimozide vs. placebo in Tourette syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 23, 161–173.
(1973). Treatment of Tourette’s syndrome with haloperidol, review of 34 cases. Archives of General Psychiatry, 28, 92–97.
(2002). Psychische Störungen bei Kindern und Jugendlichen. Lehrbuch der Kinder- und Jugendpsychiatrie. München: Urban & Fischer.
(2004). Olanzapine in the treatment of aggression and tics in children with Tourette’s syndrome – a pilot study. Journal of Child and Adolescent Psychopharmacology, 14, 255–266.
(2004). Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14, 455–463.
(2004). Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatric Drugs, 6, 33–44.
(2006). Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Movement disorders, 21, 589–598.
(2008). Aripiprazole in an case presenting with Tourette syndrome and obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 28, 452–454.
(1996). Tourette syndrome predictions of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science, 273, 1225–1227.
(2007). An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. Journal of Clinical Psychiatry, 68, 1088–1093.
(2006). A pilot study of aripiprazole in children and adolescents with Tourette’s disorder. Journal of Child and Adolescent Psychopharmacology, 16, 505–506.
(